Supercharge your AI in drug discovery with high-quality biomedical data
Virtual - EMEA - CETIf you’re working in pharma or biotech, you likely rely on artificial intelligence (AI) to help you identify new drug...
If you’re working in pharma or biotech, you likely rely on artificial intelligence (AI) to help you identify new drug...
If you’re working in pharma or biotech, you likely rely on artificial intelligence (AI) to help you identify new drug...
Join us for a 120-minute training session for new users of QIAGEN IPA. In this training, you’ll learn how to:...
Circulating tumor cells (CTCs) are cells that leave the primary tumor and are intravasated into the blood circulation system. A subset...
Scale your NGS analysis to match your sequencing throughput using our QIAGEN CLC Genomics cloud solution. In this webinar, you’ll...
Biomedical relationships knowledge is now required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial...
Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases, aid treatment decisions,...
Cancer outcome is influenced by both the tumor microenvironment and host immune response. Using QIAGEN OmicSoft Studio to access public...
This 120-minute training will teach you how to easily analyze and interpret RNA-seq data using QIAGEN CLC Genomics Workbench software...
In its latest release, QCI Interpret for Hereditary extends its market-leading content with further advancements in Artificial Intelligence (AI) for...
This 90-minute training session is about how QIAGEN Ingenuity Pathway Analysis (IPA) allows visualization of molecular intricacy and variations at...
Interested in learning about new features and functionalities that have been added to IPA lately? During this webinar, we will...
Research and development for new drugs and disease treatments can be lengthy and costly. Indication expansion can help broaden the impact of a new drug that has already been through the arduous R&D process for a disease or cancer. Drug repurposing can take this concept and expand on it by looking for other diseases with similar drug target biology. The logic is if...
This two-part series will walk you through single-cell RNA sequencing (scRNA-seq) analysis starting with a matrix file or FASTQ files and ending with a deep understanding of key pathways, regulators and cell type signatures within your data. This session is for part I of this training. In this session, you'll learn to use QIAGEN CLC Genomics Workbench to perform se...
This two-part series will walk you through single-cell RNA sequencing (scRNA-seq) analysis starting with a matrix file or FASTQ files and ending with a deep understanding of key pathways, regulators and cell type signatures within your data. In this session, we'll explore how you can take your scRNA-seq differential expression results produced from QIAGEN CLC Genom...
The composition of the immune repertoire, consisting of the T cell and B cell receptors (TCR and BCR), is important for an organism's adaptive immune system and plays a pivotal role in an individual's overall health. Understanding the complex array of TCR and BCR allows for developing precision medicine and immunotherapy. Analyzing next-generation sequencing (NGS) dat...
Take your QIAGEN Ingenuity Pathway Analysis (IPA) analyses to the next level by comparing them to your own analyses (different time points, treatments, cell lines, diseases and more) or to a library of over 100K precomputed datasets to find similar or opposite biological signatures. Identify key genes or entities and then explore how they are expressed across normal t...
In this 90-minute training, you'll learn how to perform drug treatment, toxicology and target safety assessment-related discoveries using QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN Omicsoft Lands. Using public data from GTEx (normal tissue), GEO, cancer collections and more, you'll learn how to use Omicsoft Lands to: • Investigate a drug target or biom...